Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $9.31 Consensus Target Price from Brokerages

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have been assigned a consensus recommendation of “Buy” from the ten analysts that are presently covering the company, MarketBeat reports. Eight analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $9.31.

Several brokerages have weighed in on TRVI. B. Riley reaffirmed a “buy” rating and issued a $6.00 target price on shares of Trevi Therapeutics in a research report on Monday, October 7th. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Trevi Therapeutics in a report on Thursday, December 12th. D. Boral Capital reissued a “buy” rating and set a $21.00 target price on shares of Trevi Therapeutics in a research note on Wednesday, January 8th. Finally, HC Wainwright raised their price target on shares of Trevi Therapeutics from $6.00 to $7.50 and gave the company a “buy” rating in a research note on Thursday, December 12th.

Institutional Investors Weigh In On Trevi Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MAI Capital Management boosted its stake in Trevi Therapeutics by 0.7% during the 3rd quarter. MAI Capital Management now owns 1,327,285 shares of the company’s stock valued at $4,433,000 after purchasing an additional 8,789 shares in the last quarter. Geode Capital Management LLC boosted its stake in Trevi Therapeutics by 10.2% during the third quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares in the last quarter. State Street Corp boosted its stake in Trevi Therapeutics by 5.9% during the third quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after buying an additional 53,051 shares in the last quarter. Acuta Capital Partners LLC grew its holdings in Trevi Therapeutics by 11.7% during the third quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company’s stock worth $970,000 after acquiring an additional 30,500 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in Trevi Therapeutics in the third quarter worth about $409,000. Institutional investors own 95.76% of the company’s stock.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI opened at $3.86 on Monday. Trevi Therapeutics has a 1-year low of $1.35 and a 1-year high of $4.68. The company’s fifty day moving average is $3.63 and its two-hundred day moving average is $3.24. The stock has a market capitalization of $296.72 million, a price-to-earnings ratio of -8.77 and a beta of 0.87.

Trevi Therapeutics (NASDAQ:TRVI) last issued its earnings results on Wednesday, November 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). During the same period in the previous year, the company earned ($0.08) EPS. Sell-side analysts expect that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.